

Novugen Launches Everolimus Tablets in the U.S.

Novugen is proud to announce the official launch of **Everolimus 2.5 mg, 5 mg, 7.5 mg, and 10 mg** in the U.S. market following its ANDA approval by the USFDA in October 2025.



This milestone reflects our scientific and technical capabilities in developing complex, high-barrier generics for global markets. Everolimus presents significant formulation and manufacturing challenges due to its low solubility, sensitivity to environmental conditions, and highly potent nature.

Through advanced formulation expertise and optimized manufacturing strategies, our teams successfully developed a stable, bioequivalent, and affordable product that meets stringent global regulatory standards.

As we continue expanding globally, we remain focused on our purpose: accelerating access to high-quality, affordable medicines that improve patient outcomes worldwide.